Rennova Health Inc (NASDAQ:RNVA) a vertically integrated provider firm of popular diagnostics and supportive software offerings to healthcare providers, reported that its pharmacogenomics subsidiary firm, Genomas, Inc. has been given a Patent by the USPTO.
The details
Genomas is a biomedical firm bringing DNA-Guided drug to clinical practice with offerings for the personalized prescription of medications used in the cure of diabetes, cardiovascular disease and mental illness. Its products remove trial-and-error treatment with DNA-Guided drug and enable physicians to cure with unprecedented accuracy, avoiding considerable drug side effects, enhancing efficacy and improving patient compliance.
The USPTO has accepted that a combinatorial genotype is an origination, having scopes that surpass single gene testing. It has given a patent for the combination of CYP2C19 + CYP2D6 + CYP2C9. These are the fundamental but genetically different routes of medication metabolism for most of the cardio metabolic and neuropsychiatric drugs in healthcare.
Dr. Gualberto Ruaño, the lead inventor of this patent, reported that in this patent, they define a combinatorial approach to CYP2C19, CYP2D6 and CYP2C9 genotyping as a physiological ensemble. They consider this combinatorial approach shows an improvement over the presenting gene-by-gene process by offering greater scope while still permitting for the resolution of a sole gene index. This will drive in unique research and clinical applications supporting the translation of pharmacogenomics study to personalized medicine, mainly in pain and psychiatry management where many medications depend on numerous CYP450 pathways.
A PhyzioType System comprises of three constituents: an array of natural, stable DNA polymorphisms from different genes to institute a patient’s combinatorial genotype; a portal for doctors to choose the best medication for the patient, and bio-clinical algorithms for estimating the patient’s drug response.
PhyzioType Systems can be engaged prognostically before advising drugs or diagnostically to manage subjects showing drug intolerance or resistance. Seamus Lagan, Rennova CEO reported that it is a thrilling advancement for company and is evidence of their effort to be an innovative and leading provider of healthcare offerings.
THE MORNING REPORT
Start your workday the right way with the news that matters most.
Your information is 100% secure with us and will never be shared Disclaimer & Privacy Policy
